Logo image of IKT

INHIBIKASE THERAPEUTICS INC (IKT) Stock Price, Quote, News and Overview

NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock - Currency: USD

1.77  -0.07 (-3.8%)

After market: 1.77 0 (0%)

IKT Quote, Performance and Key Statistics

INHIBIKASE THERAPEUTICS INC

NASDAQ:IKT (5/23/2025, 8:25:05 PM)

After market: 1.77 0 (0%)

1.77

-0.07 (-3.8%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.2
52 Week Low1.12
Market Cap131.58M
Shares74.34M
Float58.73M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO12-23 2020-12-23


IKT short term performance overview.The bars show the price performance of IKT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

IKT long term performance overview.The bars show the price performance of IKT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of IKT is 1.77 USD. In the past month the price decreased by -16.11%. In the past year, price decreased by -2.21%.

INHIBIKASE THERAPEUTICS INC / IKT Daily stock chart

IKT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.84 323.71B
AMGN AMGEN INC 13.09 146.07B
GILD GILEAD SCIENCES INC 13.87 133.56B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.96B
REGN REGENERON PHARMACEUTICALS 13.28 63.52B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.81B
ARGX ARGENX SE - ADR 100.1 35.88B
ONC BEIGENE LTD-ADR 6.17 26.10B
BNTX BIONTECH SE-ADR N/A 23.72B
NTRA NATERA INC N/A 20.94B
SMMT SUMMIT THERAPEUTICS INC N/A 19.20B
BIIB BIOGEN INC 7.95 18.43B

About IKT

Company Profile

IKT logo image Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Atlanta, Georgia and currently employs 15 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Company Info

INHIBIKASE THERAPEUTICS INC

3350 Riverwood Parkway Se, Suite 1900

Atlanta GEORGIA 30339 US

CEO: Milton H. Werner

Employees: 9

IKT Company Website

IKT Investor Relations

Phone: 16783923419

INHIBIKASE THERAPEUTICS INC / IKT FAQ

What is the stock price of INHIBIKASE THERAPEUTICS INC today?

The current stock price of IKT is 1.77 USD. The price decreased by -3.8% in the last trading session.


What is the ticker symbol for INHIBIKASE THERAPEUTICS INC stock?

The exchange symbol of INHIBIKASE THERAPEUTICS INC is IKT and it is listed on the Nasdaq exchange.


On which exchange is IKT stock listed?

IKT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INHIBIKASE THERAPEUTICS INC stock?

7 analysts have analysed IKT and the average price target is 8.16 USD. This implies a price increase of 361.02% is expected in the next year compared to the current price of 1.77. Check the INHIBIKASE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INHIBIKASE THERAPEUTICS INC worth?

INHIBIKASE THERAPEUTICS INC (IKT) has a market capitalization of 131.58M USD. This makes IKT a Micro Cap stock.


How many employees does INHIBIKASE THERAPEUTICS INC have?

INHIBIKASE THERAPEUTICS INC (IKT) currently has 9 employees.


What are the support and resistance levels for INHIBIKASE THERAPEUTICS INC (IKT) stock?

INHIBIKASE THERAPEUTICS INC (IKT) has a support level at 1.41 and a resistance level at 1.79. Check the full technical report for a detailed analysis of IKT support and resistance levels.


Should I buy INHIBIKASE THERAPEUTICS INC (IKT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INHIBIKASE THERAPEUTICS INC (IKT) stock pay dividends?

IKT does not pay a dividend.


When does INHIBIKASE THERAPEUTICS INC (IKT) report earnings?

INHIBIKASE THERAPEUTICS INC (IKT) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of INHIBIKASE THERAPEUTICS INC (IKT)?

INHIBIKASE THERAPEUTICS INC (IKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.98).


What is the Short Interest ratio of INHIBIKASE THERAPEUTICS INC (IKT) stock?

The outstanding short interest for INHIBIKASE THERAPEUTICS INC (IKT) is 2.44% of its float. Check the ownership tab for more information on the IKT short interest.


IKT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

IKT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IKT. IKT has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IKT Financial Highlights

Over the last trailing twelve months IKT reported a non-GAAP Earnings per Share(EPS) of -1.98. The EPS increased by 40.72% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -38.77%
ROE -42.63%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%76.71%
Sales Q2Q%N/A
EPS 1Y (TTM)40.72%
Revenue 1Y (TTM)-100%

IKT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to IKT. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners66.63%
Ins Owners4.27%
Short Float %2.44%
Short Ratio11.08
Analysts
Analysts80
Price Target8.16 (361.02%)
EPS Next Y83.03%
Revenue Next YearN/A